About FASLODEX
FASLODEX, a type of hormonal treatment known as an antiestrogen, is for hormone receptor-positive in postmenopausal women whose breast cancer has recurred or progressed following antiestrogen therapy, such as tamoxifen. FASLODEX is a hormonal therapy, not a cytotoxic chemotherapy.
In clinical trials, FASLODEX was found to be effective in women whose breast cancer recurred or progressed following other antiestrogen therapy such as tamoxifen. FASLODEX is given by intramuscular (IM) injection once a month.
The hormones estrogen and progesterone play an important role in the growth, development and function of the breasts. These hormones are naturally produced by organs in the body. To receive the signals from these hormones, normal healthy breast cells have estrogen receptors and progesterone receptors inside them. The hormones attach to these hormone receptors.
The breast cancer cells of many women diagnosed with breast cancer will have receptors for estrogen and/or progesterone. When they do, the breast cancer is said to be hormone receptor positive. When breast cancers are estrogen receptor positive, estrogen may contribute to the growth and spread of the cancer.
FASLODEX is a hormonal therapy that works by binding to estrogen receptors. In doing so, FASLODEX can block the effect estrogen has on the cancer cells. FASLODEX causes the estrogen receptor to change shape and not work as well. In addition, FASLODEX causes a decrease (downregulation) in the number of estrogen receptors.
Read about who may best benefit from taking FASLODEX, its safety and effectiveness, and how it works
To view the download, you need Adobe® Acrobat® Reader® installed. If you do not have Adobe Acrobat Reader on your computer, you can download it from the Adobe Web site.
Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.